Precision Biosciences Operating Income

Precision Biosciences (DTIL) currently reports a operating income of $-31M as of June 2026. That compares with $-84M in the prior-year period — up 63.1% year over year. Use the charts on this page to explore Precision Biosciences's operating income history and peer comparisons.

Precision Biosciences's operating income increased from $-84M to $-31M — a 63.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Precision Biosciences reported $-31M in operating income as of June 2026. That compares with $-84M in the prior-year period — up 63.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Precision Biosciences, and consider following DTIL for alerts when major investors trade the stock.

Precision Biosciences is classified in the Healthcare sector. On operating income, it currently shows $-31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DTIL with unrelated industries.